Maxwell Biotech Group

www.maxwellbiotech.com

Maxwell Biotech Group (MBG) is a development partner and financial resource for biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Our unique business model can add value to our partners’ pipelines and provide a commercialization path to one of the most lucrative emerging markets. MBG relies on an experienced international team of managers and financial and industry experts, with offices in Moscow, Boston and San Diego.

Related News

REGULATORY

LUMMUS AND BRASKEM ANNOUNCE PARTNERSHIP FOR GREEN ETHYLENE TECHNOLOGY

Braskem | April 29, 2022

news image

Lummus Technology, a global provider of process technologies and value-driven energy solutions, announced a partnership with Braskem, the largest biopolymer producer in the world, to license green ethylene technology. Lummus and Braskem will license worldwide technology to produce green ethylene and accelerate the use of bioethanol for chemicals and plastics, supporting the industry's efforts towards a carbon neutral circular economy. We are truly excited...

Read More

CELL AND GENE THERAPY

KANEKA EUROGENTEC ANNOUNCES THE SUCCESSFUL PRODUCTION OF 25G OF MRNA IN ONE BATCH

Kaneka Eurogentec | February 23, 2022

news image

Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer. Eurogentec’s GMP mRNA manufacturing service offers in vitro transcription (IVT), purification, quality control and batch release of GMP material up to 25 g scale in its current facility in Belgium. In this project Eurogentec successfully produced and purified 25 g of mate...

Read More

AKREVIA REBRANDS AS XILIO THERAPEUTICS, SNAGS $100 MILLION IN SERIES B

BioSpace | March 02, 2020

news image

Two years after Cambridge, Mass.-based Akrevia Therapeutics launched, the company has rebranded itself as Xilio Therapeutics and secured $100.5 million in a Series B financing round that will be used to advance its lead therapeutic candidates into clinical studies. The financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb) through Investigational New Drug (IND) enabling studies and into Phase I clin...

Read More

MEDICAL

GENETIC LEAP AND ASTELLAS ESTABLISH RESEARCH COLLABORATION TO DEVELOP RNA-TARGETED SMALL MOLECULES FOR ONCOLOGY TARGET

Genetic Leap | March 11, 2022

news image

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...

Read More
news image

REGULATORY

LUMMUS AND BRASKEM ANNOUNCE PARTNERSHIP FOR GREEN ETHYLENE TECHNOLOGY

Braskem | April 29, 2022

Lummus Technology, a global provider of process technologies and value-driven energy solutions, announced a partnership with Braskem, the largest biopolymer producer in the world, to license green ethylene technology. Lummus and Braskem will license worldwide technology to produce green ethylene and accelerate the use of bioethanol for chemicals and plastics, supporting the industry's efforts towards a carbon neutral circular economy. We are truly excited...

Read More
news image

CELL AND GENE THERAPY

KANEKA EUROGENTEC ANNOUNCES THE SUCCESSFUL PRODUCTION OF 25G OF MRNA IN ONE BATCH

Kaneka Eurogentec | February 23, 2022

Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer. Eurogentec’s GMP mRNA manufacturing service offers in vitro transcription (IVT), purification, quality control and batch release of GMP material up to 25 g scale in its current facility in Belgium. In this project Eurogentec successfully produced and purified 25 g of mate...

Read More
news image

AKREVIA REBRANDS AS XILIO THERAPEUTICS, SNAGS $100 MILLION IN SERIES B

BioSpace | March 02, 2020

Two years after Cambridge, Mass.-based Akrevia Therapeutics launched, the company has rebranded itself as Xilio Therapeutics and secured $100.5 million in a Series B financing round that will be used to advance its lead therapeutic candidates into clinical studies. The financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb) through Investigational New Drug (IND) enabling studies and into Phase I clin...

Read More
news image

MEDICAL

GENETIC LEAP AND ASTELLAS ESTABLISH RESEARCH COLLABORATION TO DEVELOP RNA-TARGETED SMALL MOLECULES FOR ONCOLOGY TARGET

Genetic Leap | March 11, 2022

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...

Read More